Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive treatment to levodopa in Parkinson’s disease patients to reduce OFF time.

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
PDF Mourns the Passing of Oliver Sacks
Sunday, August 30, 2015

The Parkinson’s Disease Foundation  (PDF) mourns the loss of neurologist and friend, Oliver Sacks, M.D., (pictured at left), who passed away on August 30th. 

The National Parkinson Foundation Welcomes New Board Member
Friday, August 21, 2015

MIAMI — The National Parkinson Foundation (NPF) announced the election of a new member to its Board of Directors: Dr. Guido Goldman.

The National Parkinson Foundation Launches New and Improved Parkinson.org
Monday, August 3, 2015

Premier website for the Parkinson's disease community

MIAMI — The National Parkinson Foundation announces today the official launch of a redesigned website, www.parkinson.org, devoted to increasing awareness and understanding of Parkinson's disease by offering free resources to people diagnosed with the disease and their families.

NPF Funds Community Research
Monday, June 29, 2015

The National Parkinson Foundation’s Moving Day® Fall 2014 Walks Fund Nearly $1 Million in Parkinson’s Programs

Community Grants Awarded in Atlanta, Boston, Chicago, Los Angeles, Miami and North Carolina

NPF Study Finds that Regular Exercise Can Slow Decline in Quality of Life
Wednesday, June 17, 2015

Data from the Parkinson’s Outcomes Project Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders

PDF Congratulates New NINDS Director Walter J. Koroshetz, M.D.
Tuesday, June 16, 2015

The Parkinson's Disease Foundation congratulates Walter J. Koroshetz, M.D., on being selected as the Director of the National Institute of Neurological Disorders and Stroke (NINDS). In this role, Dr. Koroshetz assumes oversight of a $1.6 billion budget for scientific research into neurological diseases, including Parkinson’s disease.

PDF Survey Finds Patient Input is Critical to Guiding Parkinson’s Research
Monday, June 15, 2015

Data Presented at 19th Annual International Parkinson and Movement Disorders Society Congress in San Diego, CA - Jun 15 2015

National Initiative to Improve the Quality of Life for People with Parkinson’s
Monday, June 1, 2015

The Edmond J. Safra National Parkinson’s Wellness Initiative Launches in Boston and Washington, D.C.

Connect.Parkinson Study Completes Enrollment
Friday, May 29, 2015

The National Parkinson Foundation Removes Barriers to Expert Parkinson’s Care Through Telemedicine

Afghanistan Veteran, PDF Champion to Complete Luxembourg IRONMAN for Parkinson’s Research on Saturday, June 20
Friday, May 29, 2015

US Army First Lieutenant Ashley Murray, a Piscataway, NJ, native, is running, biking and swimming to fight for a future without Parkinson’s disease. First Lt. Murray, an Afghanistan veteran who is currently stationed in Germany, will complete the Ergo IRONMAN 70.3 Luxembourg triathlon on Saturday, June 20 to raise funds for the Parkinson’s Disease Foundation (PDF).

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.